The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation

Health Technology Assessment

Volumn 6, Issue 16, 2002, Pages

  Woolacott, N F ^a   Jones, L ^a   Forbes, C A ^a   Mather, L C ^a   Sowden, A J ^a   Song, F J ^a   Raftery, J P ^a   Aveyard, P N ^a   Hyde, C J ^a   Barton, P M ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; CIMETIDINE; CLONAZEPAM; CONJUGATED ESTROGEN; DILTIAZEM; GLIPIZIDE; HYDROCHLOROTHIAZIDE; INSULIN; LAMOTRIGINE; LEVOTHYROXINE; LIPID; LITHIUM CARBONATE; METFORMIN; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; NIQUITIN; NIQUITIN CQ; OLANZAPINE; PROPANOL; QUINOLONE DERIVATIVE; STEROID; TEMAZEPAM; THEOPHYLLINE; TRAMADOL; UNINDEXED DRUG; DOPAMINE UPTAKE INHIBITOR; GANGLION STIMULATING AGENT;

ALLERGIC REACTION; ANXIETY NEUROSIS; CARDIOVASCULAR DISEASE; CHEWING GUM; CLINICAL TRIAL; COMORBIDITY; CONTROLLED RELEASE FORMULATION; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEALTH HAZARD; HUMAN; INSOMNIA; INTERNET; IRRITABILITY; LIPID BLOOD LEVEL; LONG TERM CARE; MEDICAL DECISION MAKING; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NICOTINE REPLACEMENT THERAPY; NOSE CONGESTION; OUTCOMES RESEARCH; PATIENT COUNSELING; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN DISEASE; SMOKING; SMOKING CESSATION; SUSTAINED RELEASE FORMULATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREMOR; UROGENITAL TRACT DISEASE; URTICARIA; XEROSTOMIA; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; TREATMENT OUTCOME;

BUPROPION; COST-BENEFIT ANALYSIS; DOPAMINE UPTAKE INHIBITORS; GANGLIONIC STIMULANTS; HUMANS; NICOTINE; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 0036374396     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6160     Document Type: Review

References (522)

1. Smoking cessation: What the health service can do
2. Current concepts in the management of smoking cessation: A review
3. Nicotine replacement therapy in patients with coronary heart disease
4. Pharmacotherapy of nicotine dependence
5. Smoking cessation: 1. An overview of research
6. Smoking cessation - Recent developments in behavioral and pharmacologic interventions
7. Nicotine replacement therapy
8. The benefits of stopping smoking and the role of nicotine replacement therapy in older patients
9. Drug and alcohol dependency
10. The impact of amfebutamone (bupropion) on National Health Service smoking cessation services
11. Drugs in substance dependence
12. Bupropion - A review of its use in the management of smoking cessation
13. Mecamylamine (a nicotine antagonist) for smoking cessation
14. Non-nicotine pharmacotherapy for smoking cessation: Mechanisms and prospects
15. Non-nicotine pharmacotherapy for smoking cessation
16. Zyban: Summary of product characteristics
17. Guidance for commissioners on the cost effectiveness of smoking cessation interventions
18. Nicotine replacement therapy for smoking cessation
19. The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence
20. Smoking cessation rates 4 years after treatment by nicotine gum and acupuncture
21. A randomized trial of naltrexone for smoking cessation
22. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking
23. Nicotine patches for pregnant smokers: A randomized controlled study
24. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation
25. Smoking cessation with four nicotine replacement regimens in a lung clinic
26. Nicotine replacement therapy for cardiac patients
27. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society
28. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum
29. A clinical trial of nicotine chewing gum for smoking cessation
30. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
31. Antidepressants for smoking cessation
32. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial
33. Bupropion SR for relapse prevention (Study 406)
34. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study
35. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride
36. Efficacy of bupropion for smoking cessation in non depressed smokers
37. A comparison of sustained-release bupropion and placebo for smoking cessation
38. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder
39. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch
40. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
41. Pharmacokinetics and pharmacodynamic effects of nicotine nasal spray devices on cardiovascular and pulmonary function
42. Autonomic effects of nicotine patch administration in habitual cigarette smokers: A double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities
43. Contribution of nicotine to acute endothelial dysfunction in long-term smokers
44. Nicotine replacement therapy for patients with coronary artery disease
45. Effects of treatment on cardiovascular risk among smokeless tobacco users
46. Pharmacodynamics and drug action: Transdermal nicotine mimics the smoking-induced endothelial dysfunction
47. Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions
48. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus
49. Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: A double-blind study in healthy smokers
50. Cardiovascular effects of nicotine gum and cigarettes assessed by ECG and echocardiography
51. Cardiovascular safety of nicotine patches, as assessed by ambulatory electrocardiographic monitoring, in patients with coronary disease who try to quit smoking
52. Cessation of long-term nicotine gum use - A prospective, randomized trial
53. Clinical evaluation of the contact sensitization potential of a transdermal nicotine system (Nicoderm)
54. Long-term effects of nicotine gum on weight gain after smoking cessation
55. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler
56. Effects of transdermal nicotine or smoking on nicotine concentrations and maternal-fetal hemodynamics
57. The hemodynamic and hematologic effects of cigarette smoking versus a nicotine patch
58. Dose-related cardiovascular and endocrine effects of transdermal nicotine
59. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking
60. High dose transdermal nicotine therapy for heavy smokers: Safety, tolerability and measurement of nicotine and cotinine levels
61. Predictors and timing of adverse experiences during transdermal nicotine therapy
62. Nicotine nasal spray for smoking cessation: Pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels
63. Evaluation of side effects after nicotine nasal spray in patients with chronic rhinitis
64. Nicotine gum use in the first year of the Lung Health Study
65. A pilot-study of the safety of 22 mg nicotine patch therapy in adolescents
66. Chewing nicotine gum for 3 months: What happens to plasma nicotine levels?
67. Physical dependence on nicotine gum: Effect of duration of use
68. The long-term effect of nicotine on the oral mucosa
69. Adverse skin reactions to nicotine in a transdermal therapeutic system
70. Transdermal nicotine suppresses cutaneous inflammation
71. Short-term effects of smoking and nicotine chewing gum on endothelium-dependent vasodilation in young healthy habitual smokers
72. Effect of 21 mg transdermal nicotine patches and smoking cessation on heart rate variability
73. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia
74. Effects of nicotine gum on coronary vasomotor responses during sympathetic stimulation in patients with coronary artery stenosis
75. Effects of the transdermal nicotine patch on normalization of HDL-C and its subfractions
76. Nicotine nasal spray and vapor inhaler: Abuse liability assessment
77. Nicotine patch use in pregnant smokers: Nicotine and cotinine levels and fetal effects
78. Transdermal nicotine replacement in pregnancy: Maternal pharmacokinetics and fetal effects
79. Risk of acute first myocardial infarction and use of nicotine patches in a general population
80. Post-marketing adverse events associated with the nicotine patch and polacrilex resin in the United States
81. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature
82. Nicotine induced exacerbation of duodenal ulcer
83. Hypercholesterolaemia after administration of nicotine chewing gum
84. Hiccups following nicotine gum use
85. Contact allergy to nicotine from a nicotine patch
86. A case of nicotine psychosis?
87. Side effects of nicotine patches
88. Rash from nicotine gum
89. Cerebral arterial narrowing with nicotine patch
90. Nicotine transdermal therapeutic system patch and anaphylactoid reaction after a wasp sting
91. Nicotine et aggravation de la myasthenie
92. Acute myocardial infarction while using the nicotine patch
93. Stroke following application of a nicotine patch
94. Le patch transdermique a la nicotine: Quelques regles de prudence d'emploi, a propos d'une observation d'effects indesirables
95. Chronic nicotine ingestion and atrial fibrillation
96. Allergic contact dermatitis from transdermal nicotine systems
97. Reactivity to nicotine patches wrongly blamed on contact allergy
98. Myocardial infarction in a patient who smoked while wearing a nicotine patch
99. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking
100. The long term effect of a nicotine sublingual tablet on the oral mucosa - A safety evaluation in a smoking cessation setting
101. Adverse events and prolonged use of nicotine gum and patch
102. Maternal and fetal cardiovascular effects of a nicotine-patch versus maternal smoking
103. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial
104. Cardiovascular effects of imipramine and bupropion in aged depressed patients
105. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients
106. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure
107. A comparison of the effects of bupropion SR and sertraline on sexual functioning in depressed outpatients
108. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment
109. Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men
110. Evaluation of sexual functioning in depressed outpatients: A double-blind comparison of sustained-release bupropion and sertraline treatment
111. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients
112. The cardiovascular profile of bupropion
113. Safety of Zyban in patients with co-existing medical and/or psychiatric conditions
114. Overview of clinically significant adverse reactions to bupropion
115. Seizures and bupropion: A review
116. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression
117. A 102-center prospective study of seizure in association with bupropion
118. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants
119. Cardiovascular effects of bupropion in depressed patients with heart disease
120. Effects of bupropion on weight in patients intolerant to previous antidepressants
121. Bupropion: An antidepressant without sexual pathophysiological action
122. Bupropion and sexual function: A placebo-controlled prospective study on diabetic men with erectile dysfunction
123. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline
124. Update on bupropion (Zyban SR)
125. Bupropion (Zyban) sustained release tablets: Reported adverse drug reactions
126. Excretion of bupropion in breast milk
127. Bupropion-induced isolated impairment of sensory trigeminal nerve function
128. Organic mental disorders associated with bupropion in three patients
129. Bupropion and nightmares
130. Mania in an elderly man treated with bupropion
131. A case of bupropion-associated delirium
132. Rhabdomyolysis associated with bupropion treatment
133. Bupropion-associated mania in a patient with HIV infection
134. Reversible dyskinesia during bupropion therapy
135. Psychoses associated with bupropion treatment
136. Mania with bupropion: A dose-related phenomenon?
137. Menstrual irregularities associated with bupropion treatment
138. Bupropion-induced psychosis
139. Acute hepatitis induced by bupropion
140. Bupropion mimics a transient ischemic attack
141. Catatonia associated with bupropion treatment
142. Serum sickness-like reaction with bupropion sustained release
143. Bupropion-SR-induced increased libido and spontaneous orgasm
144. Priapism associated with bupropion treatment
145. Bupropion and delirium
146. Seizures after bupropion overdose
147. Eosinophilia associated with bupropion
148. Bupropion and secondary mania: Is there a relationship?
149. Bupropion-induced serum sickness-like reaction
150. ECG conduction delays associated with massive bupropion overdose
151. Development of depression during placebo-controlled trials of bupropion for smoking cessation: Case reports
152. Serum sickness-like reaction with bupropion
153. Bupropion treatment-related sexual side effects: A case report
154. Tinnitus related to bupropion treatment
155. A case of bupropion-induced seizure
156. Falling backward in two elderly patients taking bupropion
157. Bupropion hydrochloride induced serum sickness-like reaction
158. Delirium associated with bupropion
159. Bupropion-induced carbohydrate craving and weight gain
160. Serum sickness induced by bupropion
161. Possible bupropion precipitation of mania and a mixed affective state
162. Antidepressant treatment during breast-feeding
163. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion
164. Cost-effectiveness of the use of Nicorette nasal spray to assist quitting smoking among heavy smokers
165. Cost-effectiveness of the use of transdermal Nicorette patches relative to GP counselling and nicotine gum in the prevention of smoking related diseases
166. Costs and effects associated with a community pharmacy-based smoking-cessation programme
167. Development of the health and economic consequences of smoking interactive model
168. Prescription of transdermal nicotine patches for smoking cessation in general practice: Evaluation of cost-effectiveness
169. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation
170. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling
171. Cost effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking
172. The cost-effectiveness of the nicotine transdermal patch for smoking cessation
173. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs
174. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation
175. Cost-effectiveness analysis of a family physician delivered smoking cessation program
176. Cost-effectiveness of treating nicotine dependence: The Mayo Clinic experience
177. The cost-effectiveness of counseling smokers to quit
178. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization
179. The health benefits of prevention: A simulation approach
180. Mortality in relation to smoking: 40 years' observations on male British doctors
181. Years of healthy life
182. Mortality in relation to smoking: 20 years observation on male British doctors
183. Predicting smoking cessation: Who will quit with and without the nicotine patch
184. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice
185. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial
186. The health care costs of smoking
187. The health care costs of smoking
188. The health care costs of smoking
189. The health care costs of smoking
190. The health care costs of smoking
191. The health care costs of smoking
192. Economic implications of smoking cessation therapies. A review of economic appraisals
193. Pharmacotherapy for opioid and cocaine abuse
194. Five-hundred life-saving interventions and their cost-effectiveness
195. Smoking and quitting with aid of nicotine replacement therapies in the English adult population
196. Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library
197. The results of direct and indirect treatment comparisons in meta-analysis of RCTs
198. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
199. Effectiveness of a transdermal nicotine system in smoking cessation studies
200. Group treatment for smoking cessation among persons with schizophrenia
201. Tobacco: An atherogenic, thrombogenic or spasmogenic factor?
202. Smoking cessation among inner-city African Americans using the nicotine transdermal patch
203. Bupropion: Study of treatment in depressed patients
204. Nicotine-replacement products in smoking cessation: A review
205. Smoking cessation: The state of the science. The utility of the transtheoretical model in guiding interventions in smoking cessation
206. Safety of nicotine patch for patients with cardiac disease
207. Bupropion-related tinnitus
208. Bupropion-associated menstrual irregularities
209. Cardiac problems during the use of nicotine patch
210. Transdermal nicotine and stroke
211. Nicotine patches safe
212. Safety of the nicotine patch in cardiac patients
213. Zyban-associated ADRs
214. Clonidine in the treatment of tobacco withdrawal. Comparison with nicotine chewing gum
215. Smoking cessation through the use of nicotine chewing gum: A double-blind trial in Thailand
216. A systematic review of the effectiveness of promoting lifestyle change in general practice
217. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy: A status report
218. Valor predictivo de la abstinencia tabaquica a los 2 meses de tratamiento
219. Comparison of the safety and efficacy of bupropion sustained release and paroxetine in elderly depressed outpatients
220. Smoking cessation with the nicotine patch
221. Smoking cessation treatments in Spain. A thirty-year perspective: 1966-1996
222. Treatment of smoking
223. Toxicity of nicotine: Implications with regard to nicotine replacement therapy
224. Nicotine and coronary heart disease
225. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy
226. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation
227. The effects of fluoxetine combined with nicotine inhalers in smoking cessation - A randomized trial
228. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial
229. Practical experiences in smoking reduction and cessation
230. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety
231. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease
232. Cardiovascular effects of antidepressants
233. Long-term effects of smoking cessation therapy combining behavior therapy and transdermal nicotine substitution
234. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: A placebo-controlled study
235. Bupropion treatment in veterans with posttraumatic stress disorder: An open study
236. Nicotine polacrilex: Clinic-based strategies with chronically ill smokers
237. Methodologic approach to adverse events applied to bupropion clinical trials
238. Safety of nicotine-containing gum
239. The short-term effect of nicotine chewing gum in patients with Parkinson's disease
240. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts
241. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)
242. Nicotine transdermal systems: Efficacy, safety and effects on nicotine withdrawal symptoms
243. Advances in non-nicotine pharmacotherapy for smoking cessation
244. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
245. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients
246. Antidepressants and seizures: Clinical anecdotes overshadow neuroscience
247. High-dose nicotine patch therapy: Percentage of replacement and smoking cessation
248. Helping your patients to quit smoking
249. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study
250. Narcotic antagonists for smoking cessation
251. A double-blind comparison of bupropion and amitriptyline in depressed inpatients
252. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation
253. Abuse potential of nicotine replacement therapies
254. Risks and benefits of nicotine to aid smoking cessation in pregnancy
255. Evaluating the tolerability of the newer antidepressants
256. Les substituts nicotiniques: Avec ou sans prescription medicale?
257. Safety and efficacy of bupropion, a novel antidepressant
258. Double-blind placebo-controlled study of bupropion hydrochloride (Wellbatrin®) in the treatment of depressed in-patients
259. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients
260. A comparison of psychological and pharmacological treatment in smoking cessation
261. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit
262. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic
263. A double-blind study of bupropion and placebo in depression
264. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder
265. Double-blind comparison of bupropion and fluoxetine in depressed outpatients
266. Efficacy and tolerability of antidepressant therapy in the old-old
267. Side-effects of nicotine patches
268. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report
269. Helping Wisconsin women quit smoking: A successful collaboration
270. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: Initial results of the Stanford Stop Smoking Project
271. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial
272. Behavioral side effects associated with antidepressants and lithium
273. Assessing the impact of a nurse-led health education intervention for people with peripheral vascular disease who smoke: The use of physiological markers, nicotine dependence and withdrawal
274. Long-term preventive care in depression: The use of bupropion in patients intolerant of other antidepressants
275. The relationship between psychopathology and smoking cessation treatment response
276. Nicotine patches improve mood and response speed in a lexical decision task
277. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia
278. Smoking status and nicotine administration differentially modify hemodynamic stress reactivity in men and women
279. Effects of dopamine agonists and antagonists on stress ulcer formation and gastric acid secretion
280. Smoking cessation among COPD and chronic bronchitis patients using the nicotine nasal spray
281. Bupropion sustained release and smoking cessation
282. Acute and long-term bupropion therapy: Response and side effects
283. The nicotine transdermal system
284. An adverse event associated with nicotine detector patch
285. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers
286. An evidence-based programme for smoking cessation: Effectiveness in routine general practice
287. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients
288. Long term use of nicotine chewing gum: Occurrence, determinants, and effect on weight gain
289. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler
290. Evaluation of the safety and efficacy of bupropion in depression
291. Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers
292. Treatment of depressed methadone maintenance patients with nefazodone: A case series
293. Double-blind comparison of bupropion vs. amitriptyline in depressed out-patients
294. Effects of bupropion on body weight
295. Treatment of spit tobacco users with transdermal nicotine system and mint snuff
296. Adverse reactions to five new antidepressants
297. Over-the-counter nicotine patch therapy for smoking cessation: Results from randomized, double-blind, placebo-controlled, and open label trials
298. Response to nicotine dependence treatment in smokers with current and past alcohol problems
299. Varying nicotine patch dose and type of smoking cessation counseling
300. Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence
301. Pharmacologic aids to smoking cessation
302. Developing treatment for tobacco addicted youth - Issues and challenges
303. Nicotine gum, 2 and 4 mg, for nicotine dependence: A double-blind placebo-controlled trial within a behavior-modification support program
304. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation
305. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study
306. Effect of nicotine nasal spray on smoking cessation: A randomized, placebo-controlled, double-blind study
307. The nicotine inhaler in smoking cessation
308. Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise
309. Treatment of bulimia with bupropion: A multicenter controlled trial
310. A clinical trial of bupropion in the treatment of depressed outpatients
311. Nicotine vs placebo gum in general medical practice
312. Transdermal nicotine - Clarifications, side-effects, and funding
313. Risk-benefit assessment of nicotine preparations in smoking cessation
314. Are higher doses of nicotine replacement more effective for smoking cessation?
315. Nicotine-replacement therapy with use of a transdermal nicotine patch - A randomized double-blind placebo-controlled trial
316. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: One-year outcome and percentage of nicotine replacement
317. Nicotine patch therapy in 101 adolescent smokers: Efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels
318. Effectiveness of a nicotine patch in helping people stop smoking: Results of a randomized trial in general practice
319. Bupropion and compulsive behavior
320. Randomised controlled trial of nicotine chewing-gum
321. Effect of nicotine, silver acetate, and ordinary chewing gum in combination with group counselling on smoking cessation
322. Nicotine gum (2 mg) plus counselling as treatment for smokers in a cessation clinic setting
323. Results of a smoking cessation program among Spanish pulmonologists and thoracic surgeons
324. Smoking cessation with a 16 h nicotine patch: Results in a group of hospital workers
325. Nasal nicotine spray in smoking cessation. Results of a multicenter study
326. Individualized treatment of smoking addiction. Results using 2 and 4 mg nicotine gum
327. Tratamiento individualizado del tabaquismo. Resultados con chicles de 2 y 4 mg de nicotina
328. Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion
329. Comparative efficacy and tolerability of nicotine replacement therapies
330. Characterization of tobacco withdrawal symptoms: Transdermal nicotine reduces hunger and weight gain
331. Smoking cessation treatment for substance misusers in early recovery
332. Safety and efficacy of bupropion in elderly patients: Preliminary observations
333. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients
334. Bupropion coadministration with electroconvulsive therapy: Two case reports
335. Do heavy smokers benefit from higher dose nicotine patch therapy?
336. Nicotine patch and paroxetine for smoking cessation
337. Bupropion for smokers - Drug is almost identical in structure to diethylpropion, a controlled drug
338. Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients
339. Multicenter private practice evaluation of the safety and efficacy of bupropion in depressed geriatric outpatients
340. Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers
341. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial
342. A comparison of nicotine delivery systems in a multimodality smoking cessation program
343. Risk of convulsions due to the use of bupropion as an aid for smoking cessation
344. Bupropion: Antidepressant with prosexual effects?
345. Nicotine patches and vascular risks
346. Self-help interventions for smoking cessation
347. Nicotine replacement combined with a novel compound (ProBAN) for smoking cessation: A pilot study
348. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence
349. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking
350. Transdermal nicotine replacement for hospitalized patients: A randomized clinical trial
351. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients
352. Secondary prevention after myocardial infarction: Reducing the risk of further cardiovascular events
353. Efficacy and safety of nicotine on Alzheimer's disease patients
354. Interventions for promoting smoking cessation during pregnancy
355. An open pilot study of bupropion and psychotherapy for the treatment of cocaine abuse in methadone-maintained patients
356. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients
357. The safety, tolerability and efficacy of transdermal nicotine (Nicotinell TTS) in initially hospitalised patients
358. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study
359. Women's Initiative for Nonsmoking (WINS) II: The intervention
360. Safety and efficacy of bupropion and nortriptyline in outpatients with depression
361. Absorption and adverse effects following topical and oral administration of three transdermal nicotine products to dogs
362. An assessment of nicotine gum as an adjunct to freedom from smoking cessation clinics
363. Plasma nicotine levels produced by chewing nicotine gum
364. A comparative study of bupropion and amitriptyline in depressed outpatients
365. The use of bupropion in hospitalized depressed patients
366. Achieving smoking cessation in nicotine-dependent individuals - Practical guidelines
367. Combined use of alcohol and nicotine gum
368. The effectiveness of antidepressants in elderly depressed outpatients: A prospective case series study
369. Utilization of nicotine nasal spray in smoking cessation
370. Safety and efficacy of bupropion combined with bromocriptine for treatment of cocaine dependence
371. Nicotine addiction: Should be recognised as the central problem of smoking
372. Interventions for smoking cessation: The outcomes are determined by the questions asked
373. Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the Lung Health Study
374. Seizure associated with bupropion and guanfacine
375. New antidepressants: Clinical studies
376. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects
377. Design and results of the initial intervention program for the Lung Health Study
378. Pharmacotherapy of smoking cessation
379. What populations are at risk when taking bupropion?
380. Use of transdermal nicotine in a state-level prescription plan for the elderly
381. Long-term efficacy and safety of bupropion
382. Office interventions for adolescent smokers
383. A critical evaluation of nicotine replacement therapy for teenage smokers
384. Effect of three smoking cessation treatments on nicotine withdrawal in 141 abstinent alcoholic smokers
385. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder
386. Low-dose nicotine nasal spray use and effects during initial smoking cessation
387. Smoking cessation in women: Special considerations
388. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms
389. Electroencephalographic effects of nicotine chewing gum in humans
390. Bupropion in depression: A tri-center placebo-controlled study
391. Evaluation of bupropion hydrochloride: The first of a new class of atypical antidepressants
392. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
393. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression
394. Comparison of nicotine chewing-gum and psychological treatments for dependent smokers
395. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
396. A comparison of the safety and efficacy of bupropion HCl and amitriptyline HCl in depressed outpatients
397. Smoking cessation
398. The transdermal nicotine patch: Results of a randomised placebo-controlled trial
399. A comparison of measures used to assess effectiveness of the transdermal nicotine patch at 1 year
400. Physicians can make a difference with smokers: Evidence-based clinical approaches
401. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder
402. A critical review of research related to family physician-assisted smoking cessation interventions
403. Transdermal nicotine reduces cigarette craving and nicotine preference
404. Transdermal nicotine facilitates smoking cessation
405. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence
406. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy
407. Brand-switching and gender effects in mecamylamone/nicotine smoking cessation treatment
408. Seizures associated with antidepressants - A review
409. Bupropion, ECT, and dopaminergic overdrive
410. Comparative tolerability profiles of the newer versus older antidepressants
411. Targeting heavy smokers in general practice: Randomised controlled trial of transdermal nicotine patches
412. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling
413. A double-blind trial of bupropion versus desipramine for bipolar depression
414. Trial of transdermal nicotine patch in smoking cessation
415. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients
416. Smoking cessation: Effectiveness of nicotine containing chewing gum. A double-blind trial
417. Combining nicotine patches and bupropion in smoking cessation therapy
418. Antidepressants, old and new: A review of their adverse effects and toxicity in overdose
419. Are there any contraindications for nicotine replacement therapy?
420. Efficacy of a nicotine nasal spray in smoking cessation: A placebo-controlled, double-blind trial
421. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial
422. Efficacy of sustained-release bupropion in neuropathic pain: An open-label study
423. Bupropion sustained release: Side effect profile
424. Safety profile of sustained-release bupropion in depression: Results of three clinical trials
425. Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies
426. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving
427. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine polacrilex gum therapy
428. Bupropion (Wellbutrin®)-imipramine study: A single-blind comparison in depressed outpatients
429. Getting the word out: Adverse consequences of nicotine replacement therapy
430. Adverse drug reaction. Nicotine polacrilex gum
431. Physician advice for smoking cessation
432. Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome
433. Smokeless tobacco cessation: Report of a preliminary trial using nicotine chewing gum
434. Smoking cessation study involving a transdermal nicotine patch. Outcomes achieved in a workplace setting and in general practice
435. The local side-effects of transdermally absorbed nicotine
436. Smoking cessation: A clinical study of the transdermal nicotine patch
437. Nicotine patch therapy in adolescent smokers
438. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark
439. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome
440. Bupropion overdose: A 3 year multi-center retrospective analysis
441. Telephone counselling for smoking cessation
442. Clinical profile of the novel antidepressant bupropion
443. Antidepressant-associated mania: A controlled comparison with spontaneous mania
444. Computer-tailored smoking cessation materials: A review and discussion
445. Comment: Niacin, nicotine, and flushing
446. Nicotine skin patch treatment and adverse reactions - Skin irritation, skin sensitization, and nicotine as a hapten
447. Randomised controlled trial of nasal nicotine spray in smoking cessation
448. Cutaneous adverse effects of transdermal therapeutic systems
449. Transdermal nicotine as maintenance therapy for ulcerative colitis
450. Safety and effectiveness of nicotine chewing gum for smoking cessation
451. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression
452. Two and four mg nicotine chewing gum and group counselling in smoking cessation: An open, randomized, controlled trial with a 22 month follow-up
453. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation
454. A double-blind trial of nicotine patches in smoking cessation
455. A double-blind trial of a nicotine inhaler for smoking cessation
456. Recycling with nicotine patches in smoking cessation
457. Recycling of hard-core smokers with nicotine nasal spray
458. Smoking cessation: Nicotine replacement, gums and patches
459. Efficacy after six months of a smoking cessation program using combined nicotine replacement therapy (patches plus chewing gum)
460. Transdermal nicotine for smoking cessation - 6-month results from 2 multicenter controlled clinical trials
461. Bupropion-amantadine-associated neurotoxicity
462. Smoking cessation: 2. Components of effective intervention
463. Development of major depression after treatment for smoking cessation
464. Preclinical toxicology of bupropion: An overview
465. Smoking cessation: Which aids are worthwhile?
466. Local and systemic skin reactions to nicotine patches
467. Nicotine containing chewing gum as an aid to give up smoking; Experiences in a general practice
468. Precision and comparability of adverse event rates of newer antidepressants
469. Efficacy and tolerability of transdermal nicotine patches in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled study
470. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: Results of a randomized placebo-controlled cross-over study
471. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation
472. Effects of maternal smoking on adverse pregnancy outcomes: Examination of the criteria of causation
473. Enhancing smoking cessation of low-income smokers in managed care
474. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly
475. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia
476. Comparison of bupropion and trazodone for the treatment of major depression
477. Double-blind, placebo-controlled trial of dextrose tablets and nicotine patch in smoking cessation
478. Individual differences in preferences for and responses to four nicotine replacement products
479. The nicotine patch in smoking cessation: A randomized trial with telephone counseling
480. Airway sensory replacement combined with nicotine replacement for smoking cessation: A randomized, placebo-controlled trial using a citric acid inhaler
481. Current concepts in smoking cessation and preventive strategies
482. The Pregnancy Registry program at Glaxo Wellcome Company
483. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects
484. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety
485. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies
486. Adverse skin reactions to the nicotine transdermal system
487. Acute effect of nicotine patch on gastric emptying of liquid and solid contents in healthy subjects
488. Smoking cessation: Part 2 - Pharmacologic approaches
489. Strategies for the treatment of antidepressant-related sexual dysfunction
490. Telephone counseling as adjuvant treatment for nicotine replacement therapy in a 'real-world' setting
491. Nicotine administration with a new oral transmucosal delivery system: A dose-response study
492. Preliminary 8-week safety and efficacy of oral transmucosal nicotine (OT-nicotine) compared to patch and gum for smoking cessation
493. Comparative efficacy and safety of bupropion and placebo in the treatment of depression
494. Nicotine gum dose and weight gain after smoking cessation
495. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs
496. Cost-effectiveness of a smoking cessation program after myocardial infarction
497. Pharmacoeconomic analysis of smoking cessation interventions